American Association for Cancer Research (AACR) Annual Meeting 2019

American Association for Cancer Research (AACR) Annual Meeting 2019

April 4, 2019

Biocytogen Highlights

  • 10 Posters highlight new IO targets (e.g. CTLA-4, OX40, CD3e), preclinical services, PK/PD studies, and antibody screening platform will be presented at AACR.
Time Abstract Full Name Abstract # Board # Category
Apr 1

8AM – 12PM

Anti-SIRPα antibodies as a   potential weapon for cancer immunotherapy via accelerated screening in   humanized mouse models 1212 9 Experimental and Molecular   Therapeutics
Apr 1

8AM – 12PM

Novel   hCD3e mouse models for preclinical pharmacology study of therapeutic   bispecific antibody  1469 21 Immunology
Apr 1

8AM – 12PM

The human immune reconstituted   B-NDG mouse models are perfect tools for CART efficacy evaluation and   therapeutic antibody preclinical pharmacology study 1052 3 Tumor Biology
Apr 1

1PM – 5PM

In   vivo drug screening platform accelerated 4-1BB agonistic antibody development 2379 3 Immunology
Apr 1

1PM – 5PM

Rapid screening of anti-OX40   antibodies for cancer immunotherapy 1924 8 Tumor Biology
Apr 2

8AM – 12PM

Novel   anti-CD40 antibodies demonstrate anti-tumor activity in humanized mouse   models 3241 21 Immunology
Apr 2

8AM – 12PM

Novel CTLA-4 antibodies of   potent antitumor activity were verified in humanized mouse models 3233 13 Immunology
Apr 2

8AM – 12PM

In   vivo efficacy and safety evaluation of anti-human PD-1 and CD40 mAbs using   double humanized PD-1/CD40 mouse model 3219 29 Immunology
Apr 2

1PM – 5PM

PK-PD Modelling of An   Anti-CTLA-4 Antibody on Immune Checkpoint Humanized Mice 3906 26 Experimental
and Molecular
Therapeutics
Apr 3

8AM – 12PM

Using   humanized B-hSIRPa/hCD47 mouse model to evaluate the efficacy and toxicity of   CD47 and SIRPa antibodies 4975 28 Immunology

Learn about Biocytogen’s enhanced capabilities: One-stop solution from concept to IND. Extensive experience in:

Event Date: March 29 - April 3, 2019 | Event Location: Atlanta, Georgia

Share:

Back to top